|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Preliminary experiments revealed that the PSA-BS18 was a potential material for targeting tumor site with superior curative effects.
|
28678638 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Reduced post-castration tumor growth rate in simvastatin-treated mice correlated with delayed time to castration-resistant progression, determined by two serum PSA doublings from post-castration nadir, when compared with xenografts in mice on control diet.
|
26238234 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Higher ROCK1 expression levels were associated with tumor stage, and Gleason grade, positive nodal stage, positive surgical margin, accelerated cell proliferation and early PSA recurrence in multivariable analysis.
|
31557128 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA density (P = .001), tumor size (P < .001), tumor percentage (P < .001), apical involvement (P = .013), and perineural invasion (P < .001) in RP specimen were higher in Group 1.
|
31269285 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In vivo, using the PSA+ LNCaP xenograft model of prostate cancer, a single i.v. dose of 1 x 10(8) particles CV787 and docetaxel in combination eliminates large preexistent distant tumors.
|
11212244 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma.
|
15283888 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recently we showed Lupeol, a triterpene, found in fruits and vegetables inhibits the growth of tumors originated from human androgen-sensitive prostate cancer (CaP) cells and decreases the serum-PSA levels in a mouse model.
|
19683515 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Significant inverse correlations were found for GRPR and increasing Gleason score, PSA value, and tumor size.
|
21739464 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To study if prostatic ductal adenocarcinoma (PDA) controlled by Grade Group (GG), PSA, and tumor volume (TV) is an independent predictor of adverse radical prostatectomy (RP) outcomes.
|
31711982 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Telomerase expression was significantly correlated with the Gleason score (p < 0.001), tumour differentiation (p < 0.001) and PSA serum levels (p = 0.002).
|
15053304 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have shown that the phenotypically undifferentiated (PSA(-/lo)) prostate cancer cell population harbors long-term self-renewing cancer stem cells (CSC) that resist castration, and a subset of the cells within the PSA(-/lo) population bearing the ALDH(hi)CD44(+)α2β1(+) phenotype (Triple Marker(+)/TM(+)) is capable of robustly initiating xenograft tumors in castrated mice.
|
27060154 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA marker monitoring is more reliable than ultrasound or fluorescence imaging for the detection of the presence of tumors in the bladder.
|
28117816 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PCA3 gene expression discriminates LN metastasis and might outperform PSA gene activity in reflecting tumor cell burden in pelvic LNs of PCa patients.
|
25769446 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
LNCaP-cl1 had higher PSA expression but lower invasiveness and tumor growth potential than LNCaP-cl5.
|
24604720 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor volume and serum PSA levels were significantly higher in the HFD group than in the LFD group (P<0.001 and P=0.006, respectively).
|
18175332 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The biochemical response (the reduction of serum PSA) as a function of the viral dose and tumor volume coverage was analyzed.
|
12504055 |
2003 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The polymorphism rs4430796 of the chromosome 17q12 appears to be a biomarker for cancer aggressiveness, increased PSA and tumor volume of PCa.
|
24627192 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA derivatives' ability to predict tumor volume varies significantly across race/ethnicity.
|
28160549 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DNA double-strand breaks were induced in cancer cells within 24 hours after radium-223 treatment, and PSA levels were significantly lower 72 hours after treatment, providing further evidence of the antitumor effects.<b>Conclusions:</b> Taken together, radium-223 therapy exhibits a dual targeting mode-of-action that induces tumor cell death and suppresses tumor-induced pathologic bone formation in tumor microenvironment of osseous CRPC growth in mice.<i></i>.
|
28364014 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also observed dramatic changes in androgen receptor (AR)-mediated pathway molecules, including prostate-specific antigen (PSA, a major biomarker of prostate cancer) and AR variants, as well as neuroendocrine-like (NE-like) and tumor stem cell-like characteristics, during androgen-independent phenotype progression.
|
24012641 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Preoperative serum PSA concentration did not correlate with tumor grade or ploidy status, but on multivariate analysis, when paired with ploidy status, independently contributed to the propensity for ECS, metastasis, and disease recurrence.
|
7954242 |
1994 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Similarly, tumor growth inhibition and PSA decrease trends were greater with VT-464 than with AA.
|
25351916 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA in tumor tissue was characterized by two immunoassays, HPLC, immunohistochemistry, reverse transcription-PCR, Southern blotting, and DNA sequencing.
|
7536128 |
1995 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Clinical indicators of aggressive prostate cancer behaviour such as PSA levels, PSA doubling time or the Gleason score of the primary tumour, as well as the androgen deprivation therapy, radiation therapy or chemotherapy status are not related to measured tracer uptake.
|
29044297 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Serum and tumor tissues exhibited reduced PSA levels.
|
21712449 |
2011 |